MDT-AP-2774
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 0.83
- sex
- F
- new_clusters
- S3
- umap1_2d
- -2.71295353
- umap2_2d
- -7.701392978
- umap1_3d
- -2.868777222
- umap2_3d
- -3.185234337
- umap3_3d
- 7.40623734
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- COMPLEMENT+0.470
- ALLOGRAFT_REJECTION+0.450
- INFLAMMATORY_RESPONSE+0.450
- INTERFERON_ALPHA_RESPONSE+0.440
- HEDGEHOG_SIGNALING+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- INTERFERON_GAMMA_RESPONSE+0.420
- TNFA_SIGNALING_VIA_NFKB+0.410
- UV_RESPONSE_DN+0.390
Top 10 suppressed
- MYC_TARGETS_V2-0.510
- E2F_TARGETS-0.500
- DNA_REPAIR-0.470
- G2M_CHECKPOINT-0.440
- MITOTIC_SPINDLE-0.290
- MYC_TARGETS_V1-0.290
- SPERMATOGENESIS-0.170
- WNT_BETA_CATENIN_SIGNALING-0.170
- UNFOLDED_PROTEIN_RESPONSE-0.070
- PEROXISOME+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YEQVW4ND | low-grade glioma | — | 0.958 |
| 2 | MDT-AP-0385 | Med | Medulloblastoma | 0.943 |
| 3 | MDT-AP-0226 | Med | Medulloblastoma | 0.935 |
| 4 | MDT-AP-2381 | Med | Medulloblastoma | 0.929 |
| 5 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.923 |
| 6 | BS_5YJEPPTP | pilocytic astrocytoma | — | 0.912 |
| 7 | BS_52426AMF | low-grade glioma | — | 0.911 |
| 8 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.910 |
| 9 | BS_55JW3HFM | Ganglioglioma | — | 0.910 |
| 10 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |